A naukri.com initiative
Bioengineer
1w
354
Image Credit: Bioengineer
Revolutionary Tiny Anticancer Weapon Developed by Penn Medicine Scientists
- Penn Medicine researchers have developed a new approach to cancer treatment using engineered small extracellular vesicles to target DR5, a receptor prevalent on many tumor cells, leading to significant reduction in cancer cell proliferation in lab tests and mouse models.
- sEVs, nano-sized particles derived from human cells, were able to activate the DR5 receptor and induce programmed cell death, making them a more effective option compared to conventional DR5-targeting antibodies. Their tumor-killing potency proved noteworthy on liver, melanoma, and ovarian cancer cell lines.
- These engineered sEVs also proved capable of attacking cancer-associated fibroblasts and myeloid-derived suppressor cells in the immunosuppressive tumor microenvironment, thereby revitalizing immune responses against solid tumors where current therapies pose significant challenges.
- The ease of manufacturing, storage, and scalability of these extracellular vesicles are an added advantage, promising broader clinical applications. Ensuring clinical-grade sEVs can be generated adequately for upcoming human trials remains a future challenge at this stage.
- Further studies and trials with human subjects are necessary to evaluate their safety and efficacy compared to conventional cancer treatments, and assessing their potential to provide a much-needed alternative for cancer patients.
- The innovative approach utilizing engineered small extracellular vesicles to target DR5 reflects a potential breakthrough in cancer immunotherapy and highlights the importance of interdisciplinary collaboration in medical research.
- This study presents a transformative development in the quest for more effective cancer therapies, marking a significant step forward in our collective fight against persistent malignancies that pose significant challenges for current medical capabilities.
- The research will provide exciting results within the scientific community and will benefit from innovative academic endeavors and patient-centered approaches to cancer therapy.
- The potential for an effective, accessible therapeutic option for cancer patients is now within reach, paving the way for a future where engineered sEVs could redefine the standards of care.
- Funding from the National Institutes of Health (CA258113, CA261608, CA114046, CA284182).
Read Full Article
21 Likes
For uninterrupted reading, download the app